CD34+ bone marrow stem cells (University of California)

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameCD34+ bone marrow stem cells (University of California)
Drug Alias NameCD34+骨髓干细胞
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Stem cell therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionHematopoietic progenitor cell antigen CD34 modulatorsStem cell replacements
TargetsHematopoietic progenitor cell antigen CD34
Therapy Area/IndicationsRetinal Vein OcclusionMacular DegenerationDiabetic Retinopathy +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of California Davis
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of California Davis
Inactive CompaniesN/A
Active IndicationsRetinal Vein OcclusionMacular DegenerationDiabetic Retinopathy +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A